Navigation Links
Popular osteoporosis drugs triple risk of bone necrosis
Date:1/15/2008

A University of British Columbia and Vancouver Coastal Health Research Institute study has found that a popular class of osteoporosis drugs nearly triples the risk of developing bone necrosis, a condition that can lead to disfigurement and incapacitating pain.

The research is the largest study of bone necrosis and bisphosphonates, a class of drugs used by millions of women worldwide to help prevent bone fractures due to osteoporosis. It is also the first study to explore the link between bone necrosis and specific brands of bisphosphonates, such as Actonel, Didrocal and Fosamax. Researchers found that all three brands had similar outcomes.

Bone necrosis, a relatively rare disease diagnosed in approximately 1 in 20,000 people per year, leads to permanent loss of blood supply to the bones. Without adequate blood supply, the bone tissue dies and causes the bone to collapse. The disease primarily affects shoulders, knees and hips at the joints, causing severe pain and immobility.

Published online by the Journal of Rheumatology today, the findings follow a recent U.S. Food and Drug Administration alert about bisphosphonates that highlighted the possibility of severe and sometimes incapacitating bone, joint and/or muscle pain in patients taking the drugs. (To view the FDA alert, visit: http://www.fda.gov/cder/drug/infopage/bisphosphonates/default.htm.)

According to the American Dental Association, more than 190 million prescriptions have been written for bisphosphonates worldwide. The drugs are promoted in direct-to-consumer advertisements on U.S. television stations.

The message for women taking these medications is to pay attention to your pain, said principal investigator Dr. Mahyar Etminan of the Centre for Clinical Epidemiology and Evaluation at UBC and VCHRI. Given the widespread use of these drugs, it is important that women and their doctors know the risks that come with taking them.

Etminan cautions that bisphosphonate use may increase in the future as the possible link between estrogen use and breast cancer prompts women to switch from estrogen therapy to bisphosphonate therapy to prevent osteoporotic bone fractures. Another reason may be the availability of new bisphosphonates that come in once-a-month or once-a-year doses.

The epidemiological study, a collaboration between UBC, VCHRI and McGill University, is based on the health records of 88,000 Quebec residents from 1996 to 2003. The team undertook the research after academic papers began linking necrosis of the jaw with the use of bisphosphonates.

This is particularly important work, said Dr. John Esdaile, professor and head, Rheumatology, UBC and scientific director, Arthritis Research Centre of Canada located at VCHRI's Centre for Hip Health.

Although the osteonecrosis side-effect is rare, the use of the bisphosphonates is very common, Esdaile adds. People taking bisphosphonates are now hearing about the potential side-effects, and this study result will permit physicians to better inform them what the order of magnitude of the risk may be.


'/>"/>

Contact: Basil Waugh
basil.waugh@ubc.ca
604-822-2048
University of British Columbia
Source:Eurekalert

Related medicine news :

1. Climate change, gender differences, health among EurekAlert! 10 Most Popular Stories in 2007
2. Will Lipodissolve Continue to Remain Popular?
3. One-Third of Popular Songs Refer to Substance Abuse
4. Giant Eagle Expands Popular Generic Prescription Program and Now Offers 400 for $4
5. Banco Popular Commits To Make A Difference Day 2007
6. Study Rates Heart Health of Popular Diet Plans
7. HSA Plans Gain Popularity as Premium Costs Rise
8. Oral osteoporosis meds appear to reduce the risk of jaw degradation
9. Wyeth Receives Approvable Letter from FDA for Bazedoxifene for the Prevention of Postmenopausal Osteoporosis
10. Many Osteoporosis Medications Prevent Fractures, But None Is Proven Best
11. High-trauma fractures in older men and women linked to osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... ... Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair ... hour by 2020 and then adjusting it yearly to increase at the same rate as ... the wage floor does not erode again, and make future increases more predictable. , The ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, MTI-GlobalStem, a provider ... and other difficult to transfect cells, announces its launch of the PluriQ™ G9™ ... Editing System is a complete system for culturing and transfecting human pluripotent ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... ITASCA, Ill. , June 23, 2016  In a startling ... states are failing their residents by lacking a comprehensive, proven plan ... , a definitive ranking of how states are tackling the ... rating to only four states – Kentucky , ... and Vermont . Of the 28 failing states, ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology: